# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Audre Lorde (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML016-SYN
- Date: 2026-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Naomi Fairweather, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Three-month survivorship visit on tamoxifen. **S**

## History of present illness

Ms. Lorde returns three months after the consultation visit. She has taken tamoxifen daily for eight months. The cooling measures and paced breathing have helped: she now has one or two mild hot flashes a day and is rarely woken at night, so she has not needed venlafaxine. Her periods are regular and lighter, with no bleeding between them. She has had no leg swelling, breathlessness, bone pain, cough, or new lumps, and no swelling or heaviness of the right arm. She walks about 30 minutes most days and has been writing and giving readings. The genetic counseling clinic has offered its first appointment in early October. **S**

| Element | Detail |
|---|---|
| Interval change | Hot flashes fewer with non-drug measures |
| Tamoxifen | Eight months, taken daily |
| Recurrence symptoms | None |
| Function | Walking about 30 minutes most days; writing and giving readings |
| Genetic counseling | First available appointment in early October |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight stable; energy good |
| Endocrine | Positive | One or two mild hot flashes a day |
| Genitourinary | Negative | No abnormal vaginal bleeding |
| Cardiovascular | Negative | No leg swelling or chest pain |
| Musculoskeletal | Negative | No bone or joint pain |
| Psychiatric | Negative | Mood good; PHQ-9 score 3 and GAD-7 score 2 |

6 systems reviewed. **S**

## Current medications

- Tamoxifen 20 mg oral tablet, one tablet by mouth once daily, planned for at least five years **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 70 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 71.6 kg; BMI 25.4 kg/m². All vital signs are synthetic.

PHQ-9: 3; GAD-7: 2. All results are synthetic.

## Change since baseline

- PHQ-9: 4 at baseline, 3 at this visit **S**
- GAD-7: 3 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Breasts and chest wall | Right chest wall flat, scar supple, no nodules; left breast without masses |
| Lymph nodes | No axillary, supraclavicular, or cervical nodes |
| Extremities | Arm circumference 29.0 cm on each side; calves soft and non-tender |
| Abdomen | Soft; liver not enlarged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Stage IA right breast cancer after mastectomy, on adjuvant tamoxifen** (C50.411). No evidence of recurrence. Low distress and anxiety scores. **S**
   - Continue tamoxifen 20 mg daily.
   - Left mammogram in September.
   - Next visit in three months.
2. **Tamoxifen side effects: mild hot flashes, improving** (Z79.810). Controlled without medicine. **S**
   - Continue non-drug measures; venlafaxine remains the option if they worsen.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Cancer-related history and physical examination | Every 3 to 6 months for the first 3 years | Completed today | No symptoms or signs of recurrence |
| Medication safety | Tamoxifen adherence and side effects | Every visit | Completed today | Taken daily for eight months |
| Survey | Vasomotor symptom assessment | Periodically on endocrine therapy | Completed today | One or two mild hot flashes a day; no medicine needed |
| Examination | Abnormal vaginal bleeding inquiry on tamoxifen | Every visit | Completed today | Regular, lighter periods; no intermenstrual bleeding |
| Examination | Venous thromboembolism symptom inquiry on tamoxifen | Every visit | Completed today | No leg swelling, calf pain, or breathlessness |
| Examination | Lymphedema assessment and risk-reduction counseling | Every visit | Completed today | No swelling; arm circumferences equal |
| Survey | Distress, depression, and anxiety screen (PHQ-9 and GAD-7) | At periodic intervals | Completed today | PHQ-9 3 and GAD-7 2, minimal; down from 4 and 3 at intake |
| Survey | Fatigue, cognitive concerns, and sexual or vaginal symptoms | At each visit or periodically | Completed today | None reported |
| Laboratory | Routine blood counts, chemistry, liver tests, and tumor markers (CEA, CA 15-3, CA 27.29) | Not recommended in asymptomatic stage I to III survivors | Not indicated | No symptoms to prompt testing; none ordered |
| Imaging | CT, bone scan, PET, or other imaging for distant spread | Not recommended in asymptomatic survivors | Not indicated | No symptoms; not ordered |
| Imaging | Diagnostic mammogram of the left breast | Yearly after mastectomy | Due | Booked for September |
| Imaging | Bone density (DXA) | Every 2 years on an aromatase inhibitor, on tamoxifen with ovarian suppression, or after chemotherapy-induced menopause | Not indicated | Premenopausal on tamoxifen alone; bone health by diet, vitamin D, and weight-bearing exercise |
| Referral | Genetic counseling | Once | Referred | Still on the waiting list three months after the request; first appointment early October. The clinic coordinator was asked to offer any earlier cancellation. No result is needed for her current care |
| Self-management | Healthy lifestyle counseling | Every visit | Completed today | Walking about 200 minutes a week; strength exercise twice a week started |

## Goal progress

- Continue tamoxifen daily with side effects she finds tolerable. In progress; target 2026-09-28. **S**
- Complete the yearly surveillance mammogram of the left breast. In progress; target 2026-09-28. **S**
- Complete germline genetic assessment, missed at diagnosis. In progress; target 2026-10-19. **S**
- Keep at least 150 minutes of activity a week and a stable weight. In progress; target 2026-09-28. **S**

## Guideline basis

- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016), American Cancer Society and American Society of Clinical Oncology
- Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update (2019), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026), Aether Forge

## Follow-up

- Left mammogram in September, then a survivorship visit. Genetic counseling in October. **S**
- Next scheduled visit 2026-09-28: survivorship visit one year after diagnosis, after the yearly mammogram of the left breast. **S**
